The Role of ITGAM in Systemic Lupus Erythematosus

Completed

• Conditions: Systemic Lupus Erythematosus

• Registration Number: NCT01230112
• Lead Sponsor: Northwell Health

Brief Summary

Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-12
• Study First Submitted: 2010-10-27
• Study First Submitted QC: 2010-10-27
• Study First Posted: 2010-10-28
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Status Verified: 2013-07
• Last Update Submitted: 2013-07-29
• Last Update Posted: 2013-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health
• Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion Criteria

• History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease
• History of cancer or lymphoma
• Current use of aspirin, prednisone, or NSAID or any immunosuppressant
• Self reported HIV

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Feinstein Institute for Medical Research; 🇺🇸 Manhasset, New York, United States